Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2026-05-02 @ 12:33 PM
Study NCT ID:
NCT04934618
Status:
UNKNOWN
Last Update Posted:
2021-06-22
First Post:
2021-06-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Sponsor:
Nanfang Hospital, Southern Medical University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NFEC-2020-024
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None